Larissa Nekhlyudov

Larissa Nekhlyudov

Auto-generated profile, based on publicly available information

Larissa Nekhlyudov

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2019 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
LNLarissa Nekhlyudov
Larissa Nekhlyudov
MMMichelle A Mollica
Michelle A Mollica
PJPaul B Jacobsen
Paul B Jacobsen
DMDeborah K Mayer
Deborah K Mayer
LSLawrence N Shulman
Lawrence N Shulman
AGAnn M Geiger
Ann M Geiger
There are now close to 17 million cancer survivors in the United States, and this number is expected to continue to grow. One decade ago the Institute of Medicine report, From Cancer Patient to Cancer Survivor: Lost in Transition, outlined 10 recommendations aiming to provide coordinated, comprehensive care for cancer survivors. Although there has been noteworthy progress made since the release of the report, gaps remain in research, clinical practice, and policy. Specifically, the recommendation calling for the development of quality measures in cancer survivorship care has yet to be fulfilled. In this commentary, we describe the development of a comprehensive, evidence-based cancer survivorship care quality framework and propose the next steps to systematically apply it in clinical settings, research, and policy.

20 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BABarbara L. Andersen
Barbara L. Andersen
CLChristina Lacchetti
Christina Lacchetti
KAKimlin Ashing
Kimlin Ashing
JBJonathan S. Berek
Jonathan S. Berek
BBBarry S. Berman
Barry S. Berman
JRJulia H. Rowland
Julia H. Rowland
PURPOSE: To update the American Society of Clinical Oncology guideline on the management of anxiety and depression in adult cancer survivors.METHODS: A multidisciplinary expert panel convened to update the guideline. A systematic review of evidence published from 2013-2021 was conducted.RESULTS: The evidence base consisted of 17 systematic reviews ± meta analyses (nine for psychosocial interventions, four for physical exercise, three for mindfulness-based stress reduction [MBSR], and one for pharmacologic interventions), and an additional 44 randomized controlled trials. Psychological, educational, and psychosocial interventions led to improvements in depression and anxiety. Evidence for pharmacologic management of depression and anxiety in cancer survivors was inconsistent. The lack of inclusion of survivors from minoritized groups was noted and identified as an important consideration to provide high-quality care for ethnic minority populations.RECOMMENDATIONS: It is recommended to use a stepped-care model, that is, provide the most effective and least resource-intensive intervention based on symptom severity. All oncology patients should be offered education regarding depression and anxiety. For patients with moderate symptoms of depression, clinicians should offer cognitive behavior therapy (CBT), behavioral activation (BA), MBSR, structured physical activity, or empirically supported psychosocial interventions. For patients with moderate symptoms of anxiety, clinicians should offer CBT, BA, structured physical activity, acceptance and commitment therapy, or psychosocial interventions. For patients with severe symptoms of depression or anxiety, clinicians should offer cognitive therapy, BA, CBT, MBSR, or interpersonal therapy. Treating clinicians may offer a pharmacologic regimen for depression or anxiety for patients who do not have access to first-line treatment, prefer pharmacotherapy, have previously responded well to pharmacotherapy, or have not improved following first-line psychological or behavioral management. Additional information is available at www.asco.org/survivorship-guidelines .

1 January 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
LNLarissa Nekhlyudov
Larissa Nekhlyudov
DODenalee M O'MAlley
Denalee M O'MAlley
SHShawna Hudson
Shawna Hudson

20 June 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LNLarissa Nekhlyudov
Larissa Nekhlyudov
PGPatricia A. Ganz
Patricia A. Ganz
NANeeraj K. Arora
Neeraj K. Arora
JRJulia H. Rowland
Julia H. Rowland

25 April 2020 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
LNLarissa Nekhlyudov
Larissa Nekhlyudov
SDSaskia Duijts
Saskia Duijts
SHShawna Hudson
Shawna Hudson
Jennifer JonesJennifer Jones
Jennifer Jones
JKJustin Keogh
Justin Keogh
MFMichael Feuerstein
Michael Feuerstein

16 September 2021 in Cancer
Verified
Journal Article
Open access
PDF file
LNLarissa Nekhlyudov
Larissa Nekhlyudov
GCGrace B. Campbell
Grace B. Campbell
KSKathryn H. H Schmitz
Kathryn H. H Schmitz
GBGabriel A. Brooks
Gabriel A. Brooks
AKAnita J. Kumar
Anita J. Kumar
Diane Von AhDiane Von Ah
Diane Von Ah
This commentary provides a concise overview of the epidemiology of cancer survivorship and work, common functional limitations experienced by cancer survivors, and evidence‐based recommendations for interventions available to improve function. It also describes the US Social Security Administration's disability claims process, its eligibility requirements, and barriers for long‐term survivors in securing approval for disability claims, and offers insights for practicing clinicians in holistically addressing functional limitations in practice.